MPT0L145-生命科学试剂-MCE

Hotline:400-820-3792Inhibitors•ScreeningLibraries•Proteinswww.MedChemEMPT0L145Cat.No.:HY-122888CASNo.:2070837-24-8分⼦式:C₂₅H₂₉Cl₃N₈O₃分⼦量:595.91作⽤靶点:PI3K;FGFR;Autophagy;CDK;ReactiveOxygenSpecies(ROS)作⽤通路:PI3K/Akt/mTOR;ProteinTyrosineKinase/RTK;Autophagy;

CellCycle/DNADamage;Immunology/Inflammation;Metabolic

Enzyme/Protease;NF-κB储存⽅式:PleasestoretheproductundertherecommendedconditionsintheCertificateofAnalysis.BIOLOGICALACTIVITY⽣物活性MPT0L145⼀个PIK3C3/FGFR抑制剂，对PIK3C3的Kd值为0.53nM。MPT0L145降低FGFR1、FGFR3及其下游蛋⽩(FRS2、ERK和Akt)的磷酸化。MPT0L145诱导G0/G1期细胞周期停滞，并降低细胞周期蛋⽩E的蛋⽩⽔平。MPT0L145促进线粒体功能障碍、ROS产⽣和DNA损伤。MPT0L145⼀种⾃噬(autophagy)抑制剂。MPT0L145显著增强癌细胞对靶向或化疗药物的敏感性。MPT0L145可⽤于癌症研究，如膀胱癌和⾮⼩细胞肺癌(NSCLC)。REFERENCES[1].ChenCH,etal.TargetingAutophagybyMPT0L145,aHighlyPotentPIK3C3Inhibitor,ProvidesSynergisticInteractiontoTargetedorChemotherapeuticAgentsinCancerCells.Cancers(Basel).2019Sep11;11(9):1345.[2].ChenCH,etal.Trichlorobenzene-substitutedazaarylcompoundsasnovelFGFRinhibitorsexhibitingpotentantitumoractivityinbladdercancercellsinvitroandinvivo.Oncotarget.2016May3;7(18):26374-87.[3].HsiehTH,etal.CombininganAutophagyInhibitor,MPT0L145,withAbemaciclibIsaNewTherapeuticStrategyinGBMTreatment.Cancers(Basel).2021Dec4;13(23):6117.[4].ChenCH,etal.DualInhibitionofPIK3C3andFGFRasaNewTherapeuticApproachtoTreatBladderCancer.ClinCancerRes.2018Mar1;24(5):1176-1189.McePdfHeightCaution:Producthasnotbeenfullyvalidatedformedicalapplications.Forresearchuseonly.Tel:400-820-3792/p>